article thumbnail

University Hospitals Researcher Develops New Score System to Better Screen and Treat HFpEF Heart Failure Patients

DAIC

mtaschetta-millane Wed, 07/31/2024 - 06:00 July 31, 2024 — A novel study co-authored by a heart failure cardiologist at University Hospitals Harrington Heart & Vascular Institute, demonstrates the effectiveness of a newly developed scoring system in identifying patients with Heart Failure with Preserved Ejection Fraction (HFpEF).

article thumbnail

Bayer to Present New Investigational Heart Failure Data, Continued Portfolio Research in Chronic Kidney Disease at ACC.25

DAIC

25 include Efficacy and safety of finerenone across the spectrum of kidney risk in heart failure with mildly reduced or preserved ejection fraction during the session;"Innovations and Insights in Heart Failure With Preserved Ejection Fraction: Emerging Therapies, Biomarkers and Mechanistic Studies."

article thumbnail

Bayer to Present New Investigational Heart Failure Data, Continued Portfolio Research

DAIC

25 include Efficacy and safety of finerenone across the spectrum of kidney risk in heart failure with mildly reduced or preserved ejection fraction during the session;"Innovations and Insights in Heart Failure With Preserved Ejection Fraction: Emerging Therapies, Biomarkers and Mechanistic Studies."

article thumbnail

Research Study on Novel Rehab Program for Heart Failure Patients, Led by Wake Forest University School of Medicine, Expands to Advocate Health Site in Chicago

DAIC

Photo courtesy of Wake Forest University School of Medicine milla1cf Thu, 02/22/2024 - 13:51 February 22, 2024 — Wake Forest University School of Medicine , the academic core of Advocate Health , is expanding another research study to Advocate Christ Medical Center , in Oak Lawn, Illinois, just outside Chicago.

article thumbnail

Highlights of ACC 2024

Cardiology Update

STEP-HFpEF DM 5 ( NCT04916470 ) explored the effects of semaglutide in obesity-related HF with preserved ejection fraction (HFpEF) and type 2 diabetes. The primary superiority endpoint was clinically relevant bleeding (Bleeding Academic Research Consortium [known as BARC] types 2, 3, or 5).

Angina 52